Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637977 | 0.94 | S1PR1 (0.34) | CFTRS1PR4S1PR1S1PR5TACR1 | |
| SCHEMBL4637728 | 0.89 | IDH1 (0.37) | IDH1GPBAR1CFTRTACR1RORC | |
| SCHEMBL4637743 | 0.88 | IDH1 (0.35) | IDH1GPBAR1GRIN2BCRHR1 | |
| SCHEMBL4637943 | 0.86 | GPBAR1 (0.37) | IDH1GPBAR1TACR1GRIN2B | |
| SCHEMBL4638641 | 0.85 | IDH1 (0.41) | IDH1CFTRS1PR1RORCCRHR1 | |
| SCHEMBL4637980 | 0.85 | IDH1 (0.36) | IDH1GPBAR1TACR1GRIN2B | |
| SCHEMBL4638099 | 0.84 | IDH1 (0.36) | IDH1CNR2CFTRS1PR1S1PR5 | |
| SCHEMBL4637784 | 0.84 | IDH1 (0.37) | IDH1GPBAR1CFTRTACR1RORC | |
| SCHEMBL4639496 | 0.83 | CFTR (0.32) | GPBAR1CFTR | |
| SCHEMBL4639054 | 0.83 | ALDH1A1 (0.36) | CFTRS1PR4S1PR1S1PR5TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501808-B1 | TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050239776-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1501808-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091227-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239776-A1 | Tachykinin receptor antagonists | TACR2, TACR1, PROKR1 | IDH1 4314/4885GPBAR1 101/4885CNR2 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.